Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
AAPG
AAPG
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest AAPG ETF News Today | Earnings, Events & Price Alerts
AAPG News
Ascentage Pharma's APG-3288 IND Approved, Initiating Clinical Study
Feb 05 2026
Newsfilter
Ascentage Pharma's Dual-Engine Growth: Global Innovation Strategy for 2026
Jan 15 2026
Globenewswire
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Ascentage Pharma's APG-3288 Receives FDA IND Clearance for Clinical Study
Jan 07 2026
Globenewswire
Novo Nordisk Receives FDA Approval for Wegovy, Shares Surge 8.6%
Dec 23 2025
Benzinga
Cementos Pacasmayo, Rezolve AI, Emerald Holding, and Other Major Stocks Rising on Monday
Dec 16 2025
Benzinga
Ascentage Pharma Reports Four-Year Efficacy Data for Olverembatinib
Dec 09 2025
Newsfilter
Ascentage Pharma's Olverembatinib Shows Significant Efficacy with 21.2 Months EFS
Dec 09 2025
Globenewswire
Ascentage Pharma Presents 66% Efficacy of Olverembatinib at ASH Meeting
Dec 09 2025
Globenewswire
Ascentage Pharma Reports Strong Efficacy of Olverembatinib in CML Treatment
Dec 09 2025
Globenewswire
Ascentage Pharma Presents 66% Efficacy of Olverembatinib at ASH Conference
Dec 09 2025
Newsfilter
Ascentage Pharma Reports Olverembatinib Efficacy Data with 76.7% CCyR in CML Patients
Dec 09 2025
Newsfilter
Ascentage Pharma's Lisaftoclax Shows 31.8% Efficacy in Myeloid Malignancies
Dec 08 2025
Newsfilter
Ascentage Pharma's Lisaftoclax Shows 31.8% Efficacy in Myeloid Malignancies
Dec 08 2025
Globenewswire
ASH 2025: Ascentage Pharma Shares Promising Results from Phase Ib/II Trial of Bcl-2 Inhibitor Lisaftoclax in Patients with Myeloid Malignancies Previously Treated with Venetoclax
Dec 08 2025
Yahoo Finance
Ascentage Pharma's Lisaftoclax Shows 62.5% ORR in BTK-Refractory CLL/SLL Patients
Dec 06 2025
Newsfilter
Show More News
